CTOR

Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.